Luke Miels, GSK chief commercial officer

GSK picks up Scynex­is' FDA-ap­proved an­ti­fun­gal drug for $90M up­front

GSK is dish­ing out $90 mil­lion cash to add an an­ti­fun­gal drug to its com­mer­cial port­fo­lio, in a deal spot­light­ing the phar­ma gi­ant’s grow­ing fo­cus on in­fec­tious dis­eases.

The up­front will lock in an ex­clu­sive li­cense to Scynex­is’ Brex­afemme, which was ap­proved in 2021 to treat a yeast in­fec­tion known as vul­vo­vagi­nal can­didi­a­sis, ex­cept in Chi­na and cer­tain oth­er coun­tries where Scynex­is al­ready out-li­censed the drug.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters